Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

Autor: Guido Kobbe, Ellen Wollmer, A Finck, Markus Ditschkowski, Nadezda Basara, Andreas Neubauer, Martin F. Fey, Peter Dreger, Sebastian Scholl, Helmut R. Salih, Ralf G. Meyer, Michael Lübbert, Jürgen Finke, Andreas Burchert, S K Metzelder, Thomas Pabst, Tobias Schroeder, Katharina Götze, Aristoteles Giagounidis
Rok vydání: 2017
Předmět:
Oncology
Male
Cancer Research
Time Factors
Medizin
Internal tandem duplication
Kaplan-Meier Estimate
0302 clinical medicine
Recurrence
Risk Factors
hemic and lymphatic diseases
Germany
610 Medicine & health
Remission Induction
Middle Aged
Sorafenib
Leukemia
Myeloid
Acute
Treatment Outcome
Tandem Repeat Sequences
030220 oncology & carcinogenesis
Cohort
Disease Progression
Female
Stem cell
Myeloid leukaemia
psychological phenomena and processes
Flt3 itd
medicine.drug
Adult
Niacinamide
medicine.medical_specialty
Adolescent
Antineoplastic Agents
Disease-Free Survival
03 medical and health sciences
Young Adult
Internal medicine
Long term survival
medicine
Biomarkers
Tumor
Humans
Transplantation
Homologous
neoplasms
Protein Kinase Inhibitors
Aged
Retrospective Studies
business.industry
Phenylurea Compounds
Transplantation
fms-Like Tyrosine Kinase 3
Immunology
business
030215 immunology
Stem Cell Transplantation
Zdroj: European journal of cancer (Oxford, England : 1990). 86
ISSN: 1879-0852
Popis: Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD–positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD–positive AML relapsing after allo-SCT.
Databáze: OpenAIRE
Externí odkaz: